Newsfeeds - Spark Newswire

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Wednesday, Aug. 11, 2021: TAK, SEER, REGN, PSTI, PSTG, NVS, TWTR, NTDOY, MCRB, DOCU, BIDU, NFLX, GRMN

August 12, 9:27 AM

Takeda Pharmaceutical (TAK) - 189,804 Seer (SEER) - 7,800 Regeneron Pharmaceuticals (REGN) - 13,326 Pluristem Therapeutics (PSTI) - 45,155 Pure Storage (PSTG) - 131,501 Novartis (NVS) - 86,320 Twitter (TWTR) -

BIDU

1 minute read

Cathie Wood’s ARK Invest Posts Fund Sales For Tuesday, Aug. 10, 2021: SEER, TAK, RHHBY, REGN, PSTG, NVS, CLLS, BMY, TXG, SQ, SHOP, SE, NTDOY, MCRB, DOCU, NVDA, NFLX, BABA

By Michael Horton

August 11, 10:15 AM

Seer (SEER) - 121,042 Shares Takeda Pharmaceutical (TAK) - 116,467 Roche (RHHBY) - 394,655 Regeneron Pharmaceuticals (REGN) - 7,402 Pure Storage (PSTG) - 136,940 Novartis (NVS) - 53,188 Cellectis (CLLS) -

BABA

1 minute read

Takeda To Lead Finch-Partnered Microbiome IBD Drug

By Vandana Singh

August 10, 3:54 PM

Finch Therapeutics Group Inc (NASDAQ:FNCH) announced that Takeda Pharmaceutical Company Limited (NYSE:TAK) has elected to take the lead on the…

FNCH

2 minute read

News

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program

By Benzinga Newsdesk

August 10, 7:11 AM

Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a

FNCH

3 minute read

Takeda Highlights Publication Of Final Results From Phase 3 HELP Study Of TAKHZYRO

By Bill Haddad

August 5, 7:12 AM

− The Phase 3 HELP Study™ Open-label Extension (OLE) showed preventative treatment with TAKHZYRO markedly reduced the frequency of hereditary angioedema (HAE) attacks by 87.4 percent overall

TAK

2 minute read

Movers

Analyzing Takeda Pharmaceutical’s Unusual Options Activity

By Benzinga Insights

August 3, 3:40 PM

Shares of Takeda Pharmaceutical (NYSE:TAK) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $16.52.

TAK

2 minute read

Legal
News

Takeda Shares Up 2% Monday; Co. Late Sunday Announced Received Decision By Irish Tax Appeals Commission Related To Tax Assessment On Break Fee Shire Received From AbbVie: Court To Uphold 2014 Ruling

By Benzinga Newsdesk

August 2, 11:34 AM

Takeda Pharmaceutical Company Limited ((

TAK

1 minute read

Takeda Pharmaceutical Earlier Reported Q1 Sales $8.60B Beat $7.49M Estimate

By Benzinga Newsdesk

July 30, 8:53 AM

Takeda Pharmaceutical (NYSE:TAK) reported quarterly sales of $8.60 billion which beat the analyst consensus estimate of $7.49 million by 114.72K percent. This is a 15.31 percent increase over sales of $7.46 billion the

TAK